WATCHLONGEVITY

Saturday, June 20, 2026

Importance
62
Trust
76
Urgency
30
COMMERCIAL✓ 2 outlets

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show - Yahoo Finance

Analysis

Barclays sees Lilly's tirzepatide drugs as a big growth driver. A higher price target signals Wall Street still bets on strong sales for Mounjaro and Zepbound.

  • Barclays raised its price target on Eli Lilly to $1,400.
  • The analyst call points to tirzepatide momentum as the key driver.
$LLY
tirzepatideEli LillyBarclays
Tirzepatide News1mo
Read
Importance
45
Trust
76
Urgency
30
COMMERCIAL✓ 3 outlets

Barclays raises Eli Lilly stock price target on strong tirzepatide sales - Investing.com Canada

Barclays raised its stock price target for Eli Lilly, citing strong sales of tirzepatide (a weight-loss and diabetes drug). The analyst move reflects confidence in the drug's market performance.

Analysis

Wall Street sees Lilly's tirzepatide selling well. That points to strong demand for Mounjaro and Zepbound, which helps Lilly's stock.

  • Barclays raised its price target on Eli Lilly stock
  • The change is tied to strong tirzepatide sales
$LLY
tirzepatideEli LillyBarclays
Tirzepatide News1mo
Read
Importance
55
Trust
71
Urgency
30
COMMERCIAL

Lilly’s Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays - Investing.com

Analysis

Strong sales of Lilly's GLP-1 drugs suggest the whole weight-loss market is growing fast. That is good news for Novo too, not just Lilly.

  • Barclays says Lilly's strong GLP-1 results point to a growing market
  • Analysts see the read-across as positive for Novo Nordisk
$LLY$NVO
glp-1Eli LillyNovo NordiskBarclays
Novo Nordisk News1mo
Read